Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
SEATTLE and VANCOUVER, British Columbia, March 20, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and
commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that three oral presentations featuring data from both of the Phase 3 ORCA-2 and ORCA-3 clinical
trials of cytisinicline for smoking cessation and from the Phase 2 ORCA-V1 trial for e-cigarette cessation will be presented at the Society for Research on Nicotine and Tobacco (SRNT) Annual
Meeting, being held in Edinburgh, Scotland, March 20–23, 2024.
Lesen Sie auch
Presentation Schedule and Highlights
- March 21, 2024, 11:30 AM GMT: Achieve’s Director of Clinical Operations, Roxann Becco, will present patient-reported outcomes from the Phase 3 ORCA-2 and ORCA-3 clinical trials. Data collected
include trial participants’ experiences, such as cravings and withdrawal symptoms, personal impact on overall health, and opinions on future use.
- March 22, 2024, 8:30 AM GMT: Achieve’s Chief Medical Officer and President, Dr. Cindy Jacobs, will present data from the second, completed Phase 3 ORCA-3 trial that evaluated the efficacy and
safety of cytisinicline in 792 adult smokers in the United States. Findings confirmed results from the previous Phase 3 ORCA-2 trial demonstrating that cytisinicline, when dosed at the 3mg, three
times daily schedule for either 6 or 12 weeks, increased smoking abstinence when compared with placebo and was very well-tolerated with no treatment-related serious adverse events reported.
- March 23, 2024, 9:45 AM GMT: Dr. Nancy Rigotti, ORCA-V1 Principal Investigator and Professor of Medicine at Harvard Medical School and Director of Tobacco Research and Treatment Center, Massachusetts General Hospital, will present data from the Phase 2 ORCA-V1 trial. ORCA-V1 evaluated the effectiveness and safety of cytisinicline in users of nicotine e-cigarettes who wanted to quit vaping. Similar to the efficacy and tolerability findings observed in the combustible cigarette cessation Phase 3 trials, ORCA-V1 participants who received cytisinicline had increased successful vaping cessation rates, compared with placebo, and reported minimal rates of adverse events.
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte